Literature DB >> 28977083

Quality of life in breast cancer survivors.

Weruska Alcoforado Costa1, José Eleutério2, Paulo César Giraldo3, Ana Katherine Gonçalves1.   

Abstract

OBJECTIVE: To evaluate the influence of functional capacity (FC) and how it affects quality of life (QoL) in breast cancer survivors.
METHOD: A total of 400 breast cancer survivors were studied - 118 without metastasis, 160 with locoregional metastasis and 122 with distant metastasis. The European Organization for Research and Treatment for Cancer Quality of Life Questionnaire--Core 30 (EORTC QLQ-C30), Breast Cancer-Specific (EORTC QLQ-BR23), and the Karnofsky Performance Scale (KPS) were used to evaluate FC and QoL.
RESULTS: Women with distant metastases presented lower KPS 75.3 (SD=12.5) (p<0.001). For QLQ-C30, the mean of the Functional Scale for patients with distant metastasis was 57 (SD=19) (p<0.001), and the mean of the Symptom Scale for patients with distant metastasis was 37 (SD=20) (p<0.001). Both the scales for pain and fatigue showed the highest mean in the groups. For the Global Health Scale, patients without metastasis scored a mean of 62 (SD=24) points, while those with locoregional metastases scored a mean of 63 (SD=21.4), and distant metastasis scored 51.3 (SD=24) points. In the group with distant metastases, 105 (87%) had pain, and the average KPS was 74 (SD=12.0) (p=0.001).
CONCLUSION: Breast cancer was associated with decreased FC, compromised QoL in women with locoregional and distant metastases compared to those without metastasis.

Entities:  

Mesh:

Year:  2017        PMID: 28977083     DOI: 10.1590/1806-9282.63.07.583

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  7 in total

1.  Factors associated with upper limb dysfunction in breast cancer survivors.

Authors:  Thais Cristina Siqueira; Simone Pedrozo Frágoas; Andreia Pelegrini; Ana Rosa de Oliveira; Clarissa Medeiros da Luz
Journal:  Support Care Cancer       Date:  2020-08-17       Impact factor: 3.603

2.  Comparative evaluation of analgesic sparing efficacy between dexmedetomidine and clonidine used as adjuvant to ropivacaine in thoracic paravertebral block for patients undergoing breast cancer surgery: A prospective, randomized, double-blind study.

Authors:  Anindya Mukherjee; Anjan Das; Nairita Mayur; Chiranjib Bhattacharyya; Hirak Biswas; Tapobrata Mitra; Sandip Roybasunia; Subrata Kumar Mandal
Journal:  Saudi J Anaesth       Date:  2018 Oct-Dec

3.  Female Breast Cancer Patients, Mastectomy-Related Quality of Life: Experience from Ethiopia.

Authors:  Engida Abebe; Kassaw Demilie; Befekadu Lemmu; Kirubel Abebe
Journal:  Int J Breast Cancer       Date:  2020-04-09

4.  Quality of life and its influencing factors among breast cancer patients at Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia.

Authors:  Mikiyas Amare Getu; Changying Chen; Panpan Wang; Eva Johanna Kantelhardt; Adamu Addissie
Journal:  BMC Cancer       Date:  2022-08-17       Impact factor: 4.638

5.  Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom.

Authors:  Helena Carreira; Rachael Williams; Harley Dempsey; Susannah Stanway; Liam Smeeth; Krishnan Bhaskaran
Journal:  J Cancer Surviv       Date:  2020-10-21       Impact factor: 4.442

Review 6.  Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors.

Authors:  Sahar Zaidi; Showket Hussain; Shalini Verma; Zubia Veqar; Asiya Khan; Sheeraz Un Nazir; Neha Singh; Jamal Ali Moiz; Pranay Tanwar; Anurag Srivastava; G K Rath; Ravi Mehrotra
Journal:  Front Oncol       Date:  2018-01-11       Impact factor: 6.244

7.  Mediating effects of shoulder-arm exercise on the postoperative severity of symptoms and quality of life of women with breast cancer.

Authors:  I-Hui Chen; Chia-Hui Wang; Shu-Yi Wang; Sue-Yueh Cheng; Tzu-Jou Yu; Shu-Fen Kuo
Journal:  BMC Womens Health       Date:  2020-05-11       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.